Thanks for sharing this great article Kate. A few things jump out: 1) There is still a lot of misunderstanding around liver disease, and it's promising to see conditions like metabolic liver disease attracting more attention in the general media. This article explains the issues perfectly! A huge percentage of people with liver disease do not drink alcohol. 2) There is a danger that when we talk about 1 in 3 people having liver disease, policymakers become paralyzed by the scale of the issue. It's important to note that whilst, according to some reports, 30% of us have some degree of excess fat in our livers, not all will progress to cirrhosis, cancer or liver failure. 3) This is an urgent issue that needs addressing now. Liver-related mortality rates are trending in the wrong direction, unlike most other diseases. More people are developing steatotic (fatty) liver disease, and as comorbidities (like type 2 diabetes) become more common, people are getting sicker, quicker. Add to this the advent of new treatments including Madrigal Pharmaceuticals Resmetirom. We think that one of the keys to getting ahead of this Tsunami* (*credit Roger Green) lies in intelligence gathering and deployment. If you can use real-world data to recognize the patterns in those cases that do progress from simple steatosis to advanced disease, we're no longer talking about treating 1 in 3. We can then use a case-finding approach, and historic blood tests to find these high-risk people BEFORE they progress. “The life depends on the liver”. We couldn't have said it better ourselves. #liverdisease #publichealth #FattyLiver p.s. Thanks to New Scientist for yet another great article.
Interesting article in my Apple News Top Stories this morning about awareness of non-alcohol liver disease and approaches to increasing early diagnosis. Underlines the importance of the work Stalis is doing at with Predictive Health Intelligence. #liverdisease #publichealth
